Endonovo Therapeutics Financials
| ENDV Stock | USD 0.0007 0.0001 12.50% |
Endonovo |
Understanding current and past Endonovo Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Endonovo Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Endonovo Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Endonovo Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Endonovo Therapeutics. Check Endonovo Therapeutics' Beneish M Score to see the likelihood of Endonovo Therapeutics' management manipulating its earnings.
Endonovo Therapeutics Stock Summary
Endonovo Therapeutics competes with Bio Path, Cingulate, Purple Biotech, Soleno Therapeutics, and Genelux Common. Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California. Endonovo Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US29272H3003 |
| Business Address | 6320 Canoga Avenue, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.endonovo.com |
| Phone | 800 489 4774 |
| Currency | USD - US Dollar |
Endonovo Therapeutics Key Financial Ratios
There are many critical financial ratios that Endonovo Therapeutics' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Endonovo Therapeutics reports annually and quarterly.| Return On Asset | -1.1 | |||
| Beta | 0.49 | |||
| Z Score | -16.0 |
Endonovo Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Endonovo Therapeutics's current stock value. Our valuation model uses many indicators to compare Endonovo Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Endonovo Therapeutics competition to find correlations between indicators driving Endonovo Therapeutics's intrinsic value. More Info.Endonovo Therapeutics is rated below average in return on asset category among its peers. It is rated below average in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Endonovo Therapeutics' earnings, one of the primary drivers of an investment's value.Endonovo Therapeutics Systematic Risk
Endonovo Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Endonovo Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Endonovo Therapeutics correlated with the market. If Beta is less than 0 Endonovo Therapeutics generally moves in the opposite direction as compared to the market. If Endonovo Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Endonovo Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Endonovo Therapeutics is generally in the same direction as the market. If Beta > 1 Endonovo Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Endonovo Therapeutics December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Endonovo Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Endonovo Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Endonovo Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Endonovo Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Endonovo Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 67.27 | |||
| Value At Risk | (20.00) | |||
| Potential Upside | 12.5 |
Additional Tools for Endonovo Pink Sheet Analysis
When running Endonovo Therapeutics' price analysis, check to measure Endonovo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Endonovo Therapeutics is operating at the current time. Most of Endonovo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Endonovo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Endonovo Therapeutics' price. Additionally, you may evaluate how the addition of Endonovo Therapeutics to your portfolios can decrease your overall portfolio volatility.